JENBURPHJenburkt Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations in India and internationally. The company offers therapeutic solutions, such as analgesic and antipyretics, anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants and antacids, aphrodisiac, atopic dermatitis, consumer division, cough and cold, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. It offers its products under the Allerzine, CartiSafe Forte, Crisbo, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, and Zydol Suspension brand names. The company also exports its products. It serves large government, semi-government institutions, missionary hospitals, and public sector enterprises. Jenburkt Pharmaceuticals Limited was incorporated in 1985 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on JENBURPH — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 38/100)
- • Revenue growth: -0.0% YoY
- • Profit growth: -24.5% YoY
- • RSI: 32
- • MACD: bearish
Bull case
- • ROE: 17.6%
- • ROCE: 20.4%
- • Debt/Equity: 0.01
- • Volatility: 27% annualized
Bear case
- • Revenue growth: -0.0% YoY
- • Profit growth: -24.5% YoY
- • RSI: 32
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Revenue growth: -0.0% YoY
- • Profit growth: -24.5% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹35.62). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.